Back to results
US 2008/0175890 A1Published application
Transdermal delivery systems
AssigneeDurect Corporation
InventorsSu Il Yum, Felix Theeuwes
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeDurect Corporation
InventorsSu Il Yum, Felix Theeuwes
Estimating the term…
Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.
1-25. (canceled)
A transdermal delivery system for administering sufentanil through the skin, wherein said system provides a dosage form rate control over flux of sufentanil from the system and a net flux of sufentanil from the system through the skin of at least about 1 μg/cm2/hour, and further wherein said system does not contain a permeation enhancer.
-60. (canceled)
A transdermal delivery system for administering sufentanil through the skin, wherein said system provides a net flux of sufentanil from the system through the skin of at least about 1 μg/cm2/hour with a coefficient of variation (ΔJN/JN) of about 50% or less when applied to a subject, and further wherein said system does not contain a permeation enhancer.
-100. (canceled)
A monolithic transdermal delivery system for administering sufentanil through the skin, said system comprising a pressure-sensitive adhesive matrix containing sufentanil in an amount above the saturation point of sufentanil in the matrix, wherein when applied to a subject, the system provides a net flux of sufentanil from the system through the skin of at least about 1 μg/cm2/hour, and further wherein the system provides a dosage form rate control over flux of sufentanil from the system but does not include a permeation enhancer or rate controlling membrane.
-112. (canceled)
Dependencies are inferred from the claim text.